T-cells Archives

News and Trends 16 May 2023

LabGenius looks to create molecules with huge increase in tumor killing ability

LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]

May 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 May 2023

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […]

May 12, 2023 - 3 minutesmins - By Jim Cornall

Fluorescence microcopy image of gamma delta T cells (green) attacking cancer cells (blue). To get tot he cancer cells, the immune cells need to navigate through a dense extracellular matrix that surrounds the tumor tissue (red). Image: Katrin Raute / University of Freiburg

News and Trends 4 May 2023

Osteoporosis drug helps T cells fight aggressive breast cancer

Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system – and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer, with limited treatment options and a high probability of recurrence. Tumor growth and relapse of TNBC are driven by breast […]

May 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 May 2023

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Vitalli Bio formed to focus on immunological disorders

Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Mark Fishman. Vitalli Bio is being […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 Mar 2023

LIfT BioSciences hails breakthrough data for treating solid tumors

LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly cited by medical professionals as being critical for potentially curing solid tumors in patients. LIfT BioSciences said this involved learning from the experience of other […]

March 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

Likang gets trial ok for China’s first personalized cancer vaccine

Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and mRNA editing product approved by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to enter the clinical stage. Likang submitted […]

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Beyond Biotech podcast 35: Rare Disease Day

As February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO Biosciences; Stefano Portolano, chief executive officer, Azafaros; and from Replay, Adrian Woolfson, executive chairman, president, and co-founder, and Lachlan MacKinnon, CEO and co-founder. Rare Disease […]

February 24, 2023

News and Trends 17 Feb 2023

Positive results for INOVIO recurrent respiratory papillomatosis trial

INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Genetic study reveals high variation in T-cell receptor genes

T-cells are central in the protection against infections and cancer. With the help of TCRs (T-cell receptors), cells recognize foreign invaders and tumor cells. “It was previously unknown how variable human TCR genes are,” said Gunilla Karlsson Hedestam, professor at the department of microbiology, tumor and cell biology at Karolinska Institutet in Sweden, and the […]

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Scancell looking to partner after positive COVID vaccine data

Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […]

February 14, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Syena created to deliver first-in-class TCR-NK cell therapy

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […]

February 14, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T-cells

LabGenius looks to create molecules with huge increase in tumor killing ability

Achilles Therapeutics’ new platform identifies most potent T-cell antigens

Osteoporosis drug helps T cells fight aggressive breast cancer

Eterna acquires allogeneic immuno-oncology platform from Exacis

Vitalli Bio formed to focus on immunological disorders

LIfT BioSciences hails breakthrough data for treating solid tumors

Likang gets trial ok for China’s first personalized cancer vaccine

Beyond Biotech podcast 35: Rare Disease Day

Positive results for INOVIO recurrent respiratory papillomatosis trial

Genetic study reveals high variation in T-cell receptor genes

Scancell looking to partner after positive COVID vaccine data

Syena created to deliver first-in-class TCR-NK cell therapy

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!